Royce & Associates LP Increases Stock Holdings in Bioventus Inc. (NYSE:BVS)

Royce & Associates LP grew its position in Bioventus Inc. (NYSE:BVS - Free Report) by 5.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 732,236 shares of the company's stock after buying an additional 34,540 shares during the quarter. Royce & Associates LP owned 0.90% of Bioventus worth $7,688,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in BVS. Plato Investment Management Ltd acquired a new position in Bioventus during the fourth quarter valued at approximately $38,000. Virtus Fund Advisers LLC bought a new position in shares of Bioventus in the 3rd quarter valued at $42,000. Quest Partners LLC acquired a new position in shares of Bioventus during the 3rd quarter worth $51,000. Quarry LP bought a new stake in shares of Bioventus during the 3rd quarter worth $59,000. Finally, Arizona State Retirement System acquired a new stake in Bioventus in the fourth quarter valued at about $109,000. Institutional investors own 62.94% of the company's stock.

Wall Street Analysts Forecast Growth

BVS has been the topic of a number of research analyst reports. Canaccord Genuity Group restated a "buy" rating and issued a $15.00 price target on shares of Bioventus in a research note on Monday, March 17th. JPMorgan Chase & Co. upgraded shares of Bioventus from an "underweight" rating to a "neutral" rating and raised their target price for the company from $12.00 to $13.00 in a research report on Tuesday, December 17th.

Remove Ads

Bioventus Trading Down 0.9 %

Bioventus stock traded down $0.09 during trading hours on Friday, hitting $9.65. The stock had a trading volume of 441,024 shares, compared to its average volume of 423,736. The business's 50 day simple moving average is $10.10 and its 200-day simple moving average is $10.99. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38. The stock has a market cap of $783.15 million, a price-to-earnings ratio of -15.82 and a beta of 0.86. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Insider Activity at Bioventus

In other Bioventus news, CEO Robert E. Claypoole sold 28,786 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $261,952.60. Following the completion of the transaction, the chief executive officer now directly owns 64,964 shares in the company, valued at approximately $591,172.40. This represents a 30.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Mark Leonard Singleton sold 6,498 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $66,214.62. Following the transaction, the chief financial officer now directly owns 118,817 shares of the company's stock, valued at approximately $1,210,745.23. This represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,950 shares of company stock worth $522,437 in the last quarter. 32.90% of the stock is owned by insiders.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.